ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0730

Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study

Osteoarthritis – Clinical Poster II (0723–0738)

8:30AM-10:30AM: Abstract Number: 0755

Satisfaction with the Process versus Outcome of Care in Total Hip and Knee Arthroplasty

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0903

Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Abstract Number: 0892

Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0509

Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Cytokines & Cell Trafficking Poster (0508–0516)

8:30AM-10:30AM: Abstract Number: 0932

Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0691

Serum Cytokine Profiles of Patients with Adult Idiopathic Inflammatory Myopathy

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0874

Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0863

Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0662

Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0614

Sex and Race Based Utilization of Healthcare for Ocular Inflammation and Infection: Comparing the Results from the Medicare and the IRIS Data

Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Abstract Number: 0597

Sex Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study

Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Abstract Number: PP08

Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making

Patient Perspectives Poster (PP01–PP09)

8:30AM-10:30AM: Abstract Number: 0545

SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells

Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

8:30AM-10:30AM: Abstract Number: 0723

Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness

Osteoarthritis – Clinical Poster II (0723–0738)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].